Results 81 to 90 of about 5,756 (231)

Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

Journal of Peptide Science, Volume 30, Issue 7, July 2024.
The development of highly affine, selective peptides and small molecules in recent years has allowed peptide drugs (PDCs) and small molecule–drug conjugates (SMDCs) to increasingly compete with antibody–drug conjugates (ADCs). This review summarises and describes integrin‐addressing PDCs and SMDCs, while highlighting points of great interest.
Jannik Paulus, Norbert Sewald
wiley   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis

BMC Cardiovascular Disorders, 2022
Background Current guidelines indicate we can consider a bridging strategy that uses intravenous, reversible glycoprotein inhibitors for patients that required surgery following recent stent implantation.
Fan Wu, Kanghua Ma, Rui Xiang, Baoru Han, Jing Chang, Zhong Zuo, Yue Luo, Min Mao   +7 more
doaj   +1 more source

Clinical and economic studies of eptifibatide in coronary stenting [Corrigendum]

Therapeutics and Clinical Risk Management, 2014
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S. Ther Clin Risk Manag. 2014;10:603–614.The TIMI abbreviation definition of “thrombosis in myocardial infarction” is incorrect for Table 2 on page 606 and Table 3 on page 607. It should read “thrombolysis in myocardial infarction”.Read the original article 
Ganesh Athappan, Pradeep K. Bhat, Sanjay Gandhi, Tilak Pasala, Prasongchai Sattayaprasert   +4 more
openaire   +5 more sources

Randomized Comparison of Eptifibatide Versus Abciximab in Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction Results of the EVA-AMI Trial [PDF]

ObjectivesThe aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI).BackgroundThe glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST ...
Banik, Norbert, Bode, Christoph, Bourkaib, Ryad, Haude, Michael, Heuer, Hubertus, Kropff, Stefan, Lablanche, Jean-Marc, Margenet, Alain, Schröder, Rolf, Teiger, Emmanuel, Zahn, Ralf, Zeymer, Uwe   +11 more
core   +1 more source

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome [PDF]

, 2010
In patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), both periprocedural acute myocardial infarction and bleeding complications have been shown to be associated with early and late mortality. Current standard
Miller, Jeffrey M, Pham, Phuong-Anh T, Pham, Phuong-Chi T, Pham, Phuong-Mai T, Pham, Phuong-Thu T, Pham, Son V   +5 more
core   +3 more sources

Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets

Small, Volume 20, Issue 12, March 22, 2024.
InP/ZnS quantum dots (QDs) can be relevant for in vivo platelet imaging. It shows that careful selection of QD phase transfer agent is critical to maintaining platelet function. These results indicate that platelet‐QD interaction can occur across a wide range of concentrations.
Hélio M. Gil, Zoe Booth, Thomas W. Price, Jessica Lee, Leigh Naylor‐Adamson, Michelle Avery, Alina Muravitskaya, Nicole Hondow, David Allsup, Jürgen E. Schneider, Khalid Naseem, Ali M. Adawi, Jean‐Sebastien G. Bouillard, Thomas W. Chamberlain, Simon D. J. Calaminus, Graeme J. Stasiuk   +15 more
wiley   +1 more source

GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin [PDF]

, 2010
Background: There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI ...
Angela Saladini, Bhatt DL, Bindo Missiroli, Bolognese L, Brener SJ, Cantor WJ, Cristina Nesta, Dangas G, De Luca G, Domenico Cuturello, Francesco Papalia, Gilchrist IC, Giugliano RP, Kushner FG, Le Pen C, Lindsey JB, Lotrionte M, Marmur JD, Michele Schiariti, O'Shea JC, Paolo Emilio Puddu, Paraskevas KI, Placido Grillo, Puddu PE, Schiariti M, Smith SC Jr, Tardiff BE, Topol EJ, Topol EJ, Valgimigli M, Wiviott SD, Wiviott SD, Zijlstra F   +32 more
core   +2 more sources

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Cancer Medicine, Volume 13, Issue 2, January 2024.
Abstract RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into
Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri   +5 more
wiley   +1 more source

Eptifibatide

Reactions Weekly
Bansal AB, Sattar Y, Patel P, Jamil RT.
europepmc   +3 more sources